USFDA accepts Bristol Myers Squibb’s application for subcutaneous nivolumab

Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor

Wipro to implement Independent Health’s Medicare prescription payment plan platform

Wipro's MPPP360 platform will assist Independent Health in streamlining the payment process to seamlessly integrate these new provisions

Moderna posts Q1 2024 revenues at US$167 million

GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)

Philips Respironics agrees to pay $1.1 billion settlement after CPAP machine recall

Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims

GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA

Submission based on results from pivotal phase III trial showing all primary endpoints met

AstraZeneca and Daiichi Sankyo’s BLA for Dato-DXd accepted in the US for treatment of breast cancer

Application based on results from the TROPION-Breast01 Phase III trial

IFF to sell Pharma Solutions business to Roquette for US$ 2.85 billion

Pharma Solutions operates 10 research and development and/or production sites globally

CuraTeQ Biologics announces the successful Phase 1 clinical study outcome of their BP11 product

Biocon Biologics secures Canada market entry date for YESAFILI

This agreement paves the way for the introduction of YESAFILI into the Canadian market

Biocon Biologics secures US market entry date for Bmab 1200

The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA